Oncocyte to Announce Third Quarter 2022 Financial Results
Oncocyte Corporation (Nasdaq: OCX) has announced the release of its third quarter 2022 financial results scheduled for November 10, 2022. A conference call and webcast will follow at 1:30 p.m. Pacific Time to discuss these results and other highlights. Oncocyte focuses on precision diagnostics to enhance patient outcomes, with proprietary tests like DetermaRx™ and DetermaIO™ aimed at improving cancer care and treatment decisions. The company also offers pharmaceutical services supporting cancer drug development.
- Oncocyte is a precision diagnostics company focused on improving cancer patient outcomes.
- The company has proprietary tests (DetermaRx™, DetermaIO™) aimed at enhancing cancer diagnosis and treatment options.
- A diverse pipeline of tests is developing for various cancer-related applications.
- None.
IRVINE, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its third quarter 2022 financial results on Thursday, November 10, 2022. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live call via telephone by dialing (877) 407-9716 for domestic callers or (201) 493-6779 for international callers, using conference ID: 13732984. The live webinar of the call may be accessed by visiting the “Events & Presentation” section of the Company’s website at https://investors.oncocyte.com. A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.
About Oncocyte
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.
Through its proprietary tests and pharmaceutical services business, the Company aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The Company’s pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, DetermaCNI™, a blood-based monitoring test, DetermaMx™, a long-term recurrence monitoring test, and VitaGraft™, a blood-based solid organ transplantation monitoring test. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.
DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and VitaGraft™ are trademarks of Oncocyte Corporation.
Investor Contact
Caroline Corner
ICR Westwicke
(415) 202-5678
caroline.corner@westwicke.com
FAQ
When will Oncocyte release its third quarter 2022 financial results?
What time is the Oncocyte conference call regarding its financial results?
What is the focus of Oncocyte Corporation?
What are some of Oncocyte's proprietary tests?
How can I access the Oncocyte conference call?
